Patterns that reliably precede a problem: underdosing (less active material than stated, documented by independent testing), mislabelling (wrong compound, wrong strength, or wrong batch on the label), and failure to provide documentation when asked. I would want the raw data before agreeing with my own summary of it.
Documentation that appears only after payment Writing it up because I had to work it out twice and would rather nobody else did.
Proposing that documentation deserves a maintained page rather than a recurring topic, and drafting the skeleton here so that the argument about scope happens before the writing rather than after.
What I think belongs on it, what does not, and the three claims that would need a citation each.
The opening post is right about the mechanism and I think understates the practical bit.
Adding a reference point for documentation. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Patterns that reliably precede a problem: underdosing (less active material than stated, documented by independent testing), mislabelling (wrong compound, wrong strength, or wrong batch on the label), and failure to provide documentation when asked.
I would want the raw data before agreeing with my own summary of it.
Documentation is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Summarising the documentation thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
This is the sort of exchange that makes the archive worth searching.
The strongest single signal available cheaply is what happens when you ask a technical question. A quantitative answer inside a working day is difficult to fake at scale.
Documentation quality as a signal: a supplier that reports method identifiers, distinguishes specification from result, and states the counter-ion form is telling you something about systems behind the document. A certificate that is a number and a signature tells you less.
Written in the hope of being told what I have missed.
Prices well below the rest of the market are a fact rather than a finding. They are worth noting and they do not establish anything on their own.
The short answer was in the first line; everything after is the working.
Post #10 answers the question as asked. The question underneath it is different.
Careful with the language on documentation. "Not detected" and "not present" are different findings and the first is a statement about the method.
Clear enough that I do not think I have a follow-up, which is unusual.
Seconded. It reads as careful rather than confident, which is the right register.
Documentation looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
I read post #16 twice before replying, because I had assumed the opposite.
A certificate that reports a specification in the result column is a documentation defect, and it is a defect people should be able to recognise without it being called anything worse.
Caveat: everything above assumes the paperwork is what it says it is.
I read post #21 twice before replying, because I had assumed the opposite.
Exaggerated claims without documentation: every compound has limits. No peptide is "100% pure" because purity is measured to finite precision. A supplier claiming implausible perfection without backing evidence is overreaching.
Correct me on the arithmetic if it is wrong; I would rather know.
Unresponsiveness: a supplier that does not reply to reasonable requests for documentation or clarification is showing you something about how they operate.
Two claims get bundled together under documentation and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Coming back to post #26, because the follow-up matters more than the original answer.
A stock listing that never changes and a lead time that never varies are both worth noticing. Real operations have variation in them.
I would rather post the uncertainty than round it away.
Picking up post #26: that is the part I would want checked first.
What would change my mind on documentation is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Safety documentation absent: a supplier that cannot provide information about sterility testing, endotoxin testing, or safety documentation when asked is raising flags.